Synthetic lethality of p97 inhibition and PSMC2-overexpressionovercomes bortezomib resistance in multiple myeloma
James J Ignatz-Hoover, Ernest Ricky Chan, Ehsan Malek, John D'Cruz, Nida Mubin, Wei Huang, Derek J Taylor, Mehmet Samur, Nikhil C. Munshi, Kenneth C. Anderson, James Joseph Driscoll
This study identifies PSMC2 overexpression as a driver of bortezomib resistance in multiple myeloma and shows that combining p97 inhibition with bortezomib overcomes this resistance.
bioRxiv · Nov 3, 2026 · PreprintCancer Biology